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health insurance status were associated with differential levels of antidepressant adher-
ence and associated health expenditure. Hispanic ethnicity was associated with 
decreased antidepressant adherence compared to non-Hispanic white (β = 12.53, P < 
0.05) and other ethnicities (β = 28.27, P < 0.01). Patient who were covered by public 
insurance had better PDC compared to uninsured patients (β = 16.23, P < 0.05). 
Patient who were covered by private insurance spent more on MDD-speciﬁ c drug 
compared to uninsured patients (β = 0.36, P < 0.05). Higher antidepressant adherence 
was associated with higher MDD-speciﬁ c drug expenditure (β = 0.03, P < 0.01). Use 
of innovative antidepressants such as SSRIs and SNRIs was associated with an increase 
in MDD-speciﬁ c drug expenditure. CONCLUSIONS: Differences in antidepressant 
adherence and health care spending across patient factors could have important policy 
implications for drug formularies and health disparities. Solutions for gaps between 
optimal and suboptimal health care for patient mental health caused by systematic 
differences in sociological factors need to be well tailored. We need policy makers to 
be engaged in designing effective policy interventions to improve patient medication 
adherence, and to fund cost-effectiveness studies to improve patient outcomes and in 
turn, reduce associated health expenditure.
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OBJECTIVES: Innovative antidepressants have been widely adopted. However, the 
differences in patient factors and antidepressant use, and associated patient health and 
work outcomes were not jointly studied. This study was trying to understand how 
patient factors and antidepressant utilization were associated with patient employment 
durations and quality of life. METHODS: A retrospective cross-sectional study was 
conducted using the 2004–2007 Medical Expenditure Panel Survey (MEPS) database. 
Proportional hazard duration models were used to examine MDD patient’s employ-
ment duration. Linear regression models were implemented to study the impacts of 
MDD patient factors and antidepressant utilization on associated patient physical and 
mental health status. RESULTS: Differences in employment duration across several 
patient factors were found. Cox proportional hazard model showed that, compared 
to uninsured patients, MDD patients covered by private insurance had a lower level 
of hazard of job termination (hazard ratio = 0.15, P < 0.01). Patients who were in 
better physical health conditions had a lower level of hazard of job termination 
(hazard ratio = 0.96, P < 0.01). Results from OLS regressions showed that, compared 
to patient without antidepressant pharmacotherapy for MDD treatment, patients who 
took innovative antidepressants such as SSRIs/SNRIs and other newer ones had a huge 
increase in MCS (β = 11.35, P < 0.01). In addition, better antidepressant adherence 
was signiﬁ cantly associated with an increase of MCS (β = 0.10, P < 0.01). CONCLU-
SIONS: This study suggested that effective policy interventions were needed for 
improving medication adherence, and the design of prescription drug beneﬁ t within 
health insurance should be tailored considering its associations with patient factors 
and related improvement in health status according to the ﬁ ndings of this study. We 
need policy makers to be engaged in designing effective policy interventions to improve 
patient medication adherence, which may in turn improve patient health status and 
labor market participation.
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OBJECTIVES: To assess cost-of-illness and patient-relevant outcomes in patients with 
dementia in different settings in the German health system. METHODS: 600 patients 
with dementia were recruited at 1) a university hospital; 2) general practitioners; 3) 
ofﬁ ce-based neurologists; 4) a regional psychiatric hospital; and 5) in long-term care 
facilities. Socio-demographic, economic and clinical parameters were assessed using a 
standardized questionnaire. Disease severity was measured by means of the Minimen-
tal Status Examination (MMSE) and the Alzheimer’s Disease Assessment Scale. Neu-
ropsychiatric status was assessed with the Geriatric Depression Scale, the 
Neuropsychiatric Inventory and the Alzheimer’s Disease Cooperative-Study-Activities 
of Daily Living. Patient’s quality of life was reported by the patient and also by the 
caregiver (employing the EuroQol and the QoL-AD instruments). RESULTS: For an 
interim analysis, 278 patients (180 female, 98 male) were available. Mean age was 
78.2 yrs and mean disease duration was 4.5 yrs (SD 3.9). On average, care was needed 
for 3.0 yrs (SD 3.1). Cognitive impairment was severest in institutionalized patients 
(MMSE 12.2 pts SD 8.2) compared to the mean of all patients (MMSE 16.9 Pts). 
Mean EQ VAS values were 60.5 pts (SD 20.2). Disease-speciﬁ c QoL-AD health status 
mean was 30.2 (SD 5.6). Health status was rated highest in long-term care facilities 
(EQ VAS) and at ofﬁ ce-based neurologists (QoL-AD). In all severity stages patients 
rated their own health status (Qol-AD) better than their relatives. The costs of anti-
dementia drugs were c45,000 per 3 months. Memantine accounted for 61%. a total 
of 41% of the patients received Memantine whereas 45% of the patients received no 
anti-dementia medication. CONCLUSIONS: Health status is considerably impaired 
in patients with dementia and their caregivers. Interestingly, caregivers often appraise 
patients’ Quality of life worse than the patients themselves. Altogether, our results 
indicate a considerable under-supply with anti-dementia drugs.
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OBJECTIVES: The Zarit Burden Inventory (ZBI) is a 22-item self-report scale fre-
quently used to asess patients’ caregiver burden on several dimensions. As a multidi-
mensional instrument the interpretation of its total score is sometimes unclear. Our 
aim was to obtain a short-ZBI unidimensional scale based on Item Response Theory 
(IRT) approaches. METHODS: The validation sample comprised 246 caregivers of 
patients diagnosed with dementia and recruited for an ongoing multi-center random-
ized clinical trial on the efﬁ cacy of psychoeducational interventions (EDUCA-2 trial). 
The pre-randomization 22-item ZBI was analyzed according to the Samejima’s graded 
response model to select the more informative items. The dimensionality of the scale 
was further tested with Conﬁ rmatory Factor Analysis (CFA). Finally, discriminant 
validity was assessed by Receiving Operator Characteristic (ROC) analysis and the 
Area Under the Curve (AUC) contrasting the short scale total score against the psy-
chological distress criterion evaluated with the General Health Questionnaire 28-item 
at 5/6 cut-off. RESULTS: A 12-item short-ZBI was selected. It covered 87% of the 
total 22-item ZBI information and showed appropriate item curve characteristics 
according to the Samejima’s model. The short-ZBI had an internal reliability of 0.89 
(Cronbach’s alpha), and was compatible with a unidimensional latent structure for 
the burden construct (CFI = 0.99; RMSEA = 0.05). According to the GHQ-28 cut-off 
131 caregivers (53% of the total sample) could be considered at high risk for develop-
ping psychological distress. The discriminant validity of the short-ZBI scale against 
that criterion was good (AUC = 0.84, 95% CI = 0.79 to 0.89) and not signiﬁ cantly 
different from the parental 22-item ZBI (p = 0.85). CONCLUSIONS: We have found 
good psychometric properties for the short-ZBI scale derived from IRT. Its unidimen-
sionality might be important to enhance its interpretation. Further psychometric 
studies, mainly on its sensitivity to change are now warranted.
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OBJECTIVES: The literature indicates that social support is protective of relapse for 
adolescents treated for substance use disorder (SUD). Unfortunately, no standard 
measure of social support exists. The objective of this research is to use factor analysis 
to elucidate the underlying factor structure of a 14-item social support scale for use 
in outcomes assessment in this treatment population. METHODS: Subjects are 517 
adolescents discharged from primary substance abuse treatment from 2004–2008. The 
data is from research conducted between 6 and 12 months post discharge via a 234-
item questionnaire that included the 14-item social support scale. The scale has ques-
tions that assess the degree to which the adolescent’s social contacts conform to norms 
of positive behavior and therefore foster non-use and recovery. The response rate was 
62 percent. RESULTS: The factorability of the scale was assessed by Keiser-Meyer-
Olkin statistic (it was 0.727, > the recommended 0.6) and by Bartlett’s test of spheric-
ity which was signiﬁ cant (x2 = 1066.89, p = 0.00001). The scale was decomposed by 
principal component factor analysis and three factors emerged. Initial Eigen values 
explained 65.6, 23.1 and 11.3 percent of the variance, respectively. Final factor solu-
tions were examined using varimax, oblimin and promax rotations with 3, 4, 5 & 6 
solutions, respectively. a three-factor solution via promax explaining 99 percent of 
the variance emerged as the best solution although results were similar using the other 
rotations. Factor 1 yielded ten items that are attributes of a peers’ potential to be 
positive a or negative inﬂ uence and thus supportive of recovery. The three items in 
Factor 2 related to emotional dimensions of social support. Factor 3 contained two 
items indicating a recovering adolescent’s ability to seek-out and establish positive 
social contacts. CONCLUSIONS: This scale is useful as a standard measure of social 
support which is an important aspect of treatment success.
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OBJECTIVES: In deciding about coverage of new medical technology, multiple clini-
cal outcomes are used to support reimbursement claims. Neither the real world value 
nor the relevance of these outcome measures for patients is systematically assessed. 
Hence, there is growing interest in the use of patient-reported outcome measures. 
Multi-criteria decision analysis, like the analytic hierarchy process (AHP), is a tech-
nique to elicit patient preferences. In the present study we used AHP to prioritize 
patient relevant endpoints related to the use of antidepressants in major depression. 
